Replimune Group Inc — 貸借対照表 (NASDAQ:REPL) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 543.1 M461.19 M646.59 M487.72 M551.33 M 負債合計 44.37 M49.96 M91.3 M113.21 M135.49 M 純資産合計 498.73 M411.23 M555.29 M374.51 M415.84 M 負債および純資産合計 543.1 M461.19 M646.59 M487.72 M551.33 M 有利子負債合計 15.85 M—31.29 M47.53 M49.18 M 純負債 -460.45 M—-549.23 M-370.93 M-433.17 M

ニュース

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

原油5％上昇、ファスナルは第1四半期決算を受け下落

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

ダウが350ポイント以上下落、ゴールドマン好決算も相場支えきれず

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study